Atlanta, GA – According to filings with the U.S. Securities and Exchange Commission, Antios Therapeutics is raising $5,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Abel De La Rosa played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Antios Therapeutics

Antios’ mission is to develop innovative therapies to treat and cure viral diseases. Antios Therapeutics is a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases. With our lead oral candidate (ATI-2173), we are aiming to develop a cure for chronic hepatitis B.

To learn more about Antios Therapeutics, visit http://www.antiostherapeutics.com/

Contact:
Abel De La Rosa, Chief Executive Officer
212-698-3616

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved